Overactive bladder (OAB) is a prevalent condition in the community, characterised by urinary urgency, frequency, and nocturia in the absence of an identifiable pathology. These symptoms result from unstable bladder contractions and have been shown in large studies to significantly affect the psychological, social, physical, and emotional well-being of both patients and their carers. Transcutaneous tibial nerve stimulation (TTNS) is a minimally invasive and well-tolerated treatment option, traditionally administered once weekly over a period of six to twelve weeks.

We conducted a retrospective review spanning eight years at a single Australian private outpatient urology clinic. Patients were prescribed daily TTNS, with or without concurrent pharmacotherapy, for 12 weeks. Baseline characteristics, including aetiology of OAB, were recorded. Treatment efficacy was assessed using the International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ-OAB). Pre- and post-treatment urinary frequency, nocturia episodes, urgency, and urge incontinence were also evaluated retrospectively.

A total of 189 patients were included, with a dropout rate of approximately 20%. The aetiology of OAB symptoms was idiopathic in 81% of cases, neurogenic in 13%, and related to interstitial cystitis in 6%. Improvements were observed in the total ICIQ-OAB score and across all domains: urinary frequency, nocturia, urgency, and urge incontinence.

An intensive 12-week course of daily TTNS was associated with significant improvement in OAB symptoms, surpassing outcomes typically reported in the existing literature. Larger-scale, multi-centre studies are recommended to validate these findings and inform best-practice treatment strategies.